Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index

ConclusionEarly switching from TACE to sorafenib therapy may prolong OS in HCC patients unresponsive to TACE. The present study indicates that the FT rate is potentially a useful index in evaluating the outcome for patients at various stages and treatment regimens.FundingBayer Yakuhin, Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research